New Issue: HSBC prices $905,000 leveraged contingent buffered enhanced notes on Bristol-Myers

By Marisa Wong

Madison, Wis., March 28 - HSBC USA Inc. priced $905,000 of 0% leveraged contingent buffered enhanced notes due April 15, 2015 linked to Bristol-Myers Squibb Co. shares, according to a 424B2 filing with the Securities and Exchange Commission.

If the stock finishes at or above the 90% knock-out level, the payout at maturity will be par plus double the stock return, subject to a contingent minimum return of 0% and a maximum return of 27.5%.

Otherwise, investors will be fully exposed to any losses.

HSBC Securities (USA) Inc. is the underwriter with J.P. Morgan Securities LLC as agent.

Issuer:	HSBC USA Inc.
Issue:	Leveraged contingent buffered enhanced notes
Underlying stock:	Bristol-Myers Squibb Co. (Symbol: BMY)
Amount:	$905,000
Maturity:	April 15, 2015
Coupon:	0%
Price:	Par
Payout at maturity:	If stock finishes at or above 90% knock-out level, par plus double return, subject to a contingent minimum return of 0% and a maximum return of 27.5%; otherwise, full exposure to any losses
Initial price:	$52.66
Pricing date:	March 26
Settlement date:	March 31
Underwriter:	HSBC Securities (USA) Inc.
Agent:	J.P. Morgan Securities LLC
Fees:	1%
Cusip:	40432XWN7

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.